RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials
Evidence from a choice-based conjoint analysis
Wood, D., Kosa, K., Brown, D., Ehrlich, O. G., Higgins, P. D. R., & Heller, C. (2020). Preferences of adult patients with inflammatory bowel disease for attributes of clinical trials: Evidence from a choice-based conjoint analysis. Crohn's & Colitis 360, 2(1), Article 048. https://doi.org/10.1093/crocol/otz048
Background: Clinical trial recruitment is the rate-limiting step in developing new treatments. To understand inflammatory bowel disease (IBD) patient recruitment, we investigated two questions: Do changes in clinical trial attributes, like monetary compensation, influence recruitment rates, and does this influence differ across subgroups?
Methods: We answered these questions through a conjoint survey of 949 adult IBD patients.
Results: Recruitment rates are influenced by trial attributes: small but significant increases are predicted with lower placebo rates, reduced number of endoscopies, less time commitment, open label extension, and increased involvement of participant's primary GI physician. A much stronger effect was found with increased monetary compensation. Latent class analysis indicated three patient subgroups: some patients quite willing to participate in IBD trials, some quite reluctant, and others who can be persuaded. The persuadable group is quite sensitive to monetary compensation, and payments up to US$2,000 for a 1-year study could significantly increase recruitment rates for IBD clinical trials.
Conclusions: This innovative study provides researchers with a framework for predicting recruitment rates for different IBD clinical trials.